Evidence mapPaperPMID 40403579Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

A gut response: Application of human enteroid monolayers to probe the mechanism of the goldenseal-mediated inhibition of metformin intestinal absorption.

Christopher M Arian, Eimear T O'Mahony, Preston K Manwill, Tyler N Graf, Nicholas H Oberlies, Nadja B Cech, John D Clarke, Jason G Smith, Mary F Paine, Edward J Kelly and 1 more

Erratum issuedAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Novel emerging cell and organoid systems for the study of drug metabolism and toxicity in humans.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Christopher M ArianDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington.
Eimear T O'MahonyDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington.
Preston K ManwillDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina.
Tyler N GrafDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina.
Nicholas H OberliesDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina; Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington.
Nadja B CechDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina; Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington.
John D ClarkeCenter of Excellence for Natural Product Drug Interaction Research, Spokane, Washington; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Jason G SmithDepartment of Microbiology, School of Medicine, University of Washington, Seattle, Washington.
Mary F PaineCenter of Excellence for Natural Product Drug Interaction Research, Spokane, Washington; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington.
Edward J KellyDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington; Kidney Research Institute, University of Washington, Seattle, Washington.
Kenneth E ThummelDepartment of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington; Center of Excellence for Natural Product Drug Interaction Research, Spokane, Washington. Electronic address: thummel@uw.edu.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · 1985 to 2025
$104.6M
NCATS NIH HHS UL1 TR000423NCI NIH HHS P30 CA015704NIAID NIH HHS R01 AI104920
6 · The paper itself

Abstract

Continued growth in global sales of natural products has led to an increased risk of natural product-drug interactions that can compromise drug efficacy and safety. One such natural product, goldenseal, was shown to decrease systemic exposure to a subtherapeutic dose of oral metformin in healthy adults. A follow-up study involving therapeutic metformin doses and adults with type II diabetes demonstrated a metformin dose-dependent pharmacokinetic interaction with goldenseal. These results, along with no change in metformin half-life or renal clearance in both studies, suggested that the goldenseal-metformin interaction occurred in the gut via inhibition of an unidentified saturable intestinal transport process. We used enteroid monolayers derived from the duodenum of 4 healthy human adult donors to recapitulate the goldenseal-metformin interaction in vitro and identify the transporters involved in the observed in vivo interaction. Our results implicate thiamine transporter (ThTr) 2 as the predominant transporter involved in metformin uptake through the apical membrane, accounting for approximately 45% of total metformin intracellular accumulation. Additionally, goldenseal inhibited ThTr-2, but only under subsaturating metformin dosing concentrations. The goldenseal-metformin interaction mediated under therapeutic metformin dose conditions involves a low-affinity basolateral transporter, ThTr-1, which accounts for approximately 50% of inhibitable metformin apical to basolateral flux. However, a substantial fraction of metformin flux appears to involve paracellular transport. These results further elucidate the mechanism underlying the goldenseal-metformin interaction and suggest that enteroid monolayers are a promising model to study intestinal natural product-drug interactions. SIGNIFICANCE STATEMENT: The research presented in this article demonstrates the utility of enteroid monolayers to predict and ascertain the mechanisms of drug-drug and natural product-drug interactions. Using this model, the study was able to identify the transporters (thiamine transporter-1 and thiamine transporter-2) involved in metformin absorption that are inhibited by the natural product, goldenseal, which were previously unidentified.

Indexed as

Hypoglycemic AgentsIntestinal AbsorptionIntestinal MucosaMetforminAdultDrug InteractionsFemaleHumansMaleHypoglycemic AgentsMetforminBioavailabilityEnteroidsGoldensealIntestineMetforminTransporters

Identifiers

PMID40403579
PMCPMC13095427

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.